First dengue treatment comes closer to reality

Image
ANI Washington DC
Last Updated : Sep 10 2015 | 9:13 AM IST

As per a new study, first dengue treatment has come closer to reality.

Clinical trials for a dengue fever treatment could start within a year, following a discovery by University of Queensland scientists.

Professor Paul Young said that the researchers had identified similarities in how the body reacted to dengue virus and bacterial infections, in a finding that would allow them to re-purpose existing drugs.

He noted that they have discovered that the dengue virus NS1 protein acts as a toxin in the body, in a similar manner to the way bacterial cell wall products lead to septic shock in bacterial infections.

Young added that for the past 20 to 30 years, researchers and pharmaceutical companies have been developing drug candidates to inhibit the body's damaging responses to these bacterial infections. So, drugs are already available that have gone through phase three clinical trials.

Dengue virus is estimated to infect up to 400 million people globally each year. The World Health Organisation ranks it as the most important mosquito-borne viral disease in the world.

Given increased international travel and the prospect of climate change extending the range of the dengue mosquito, more people will be at risk, he said.

Researcher Naphak Modhiran said that she hopes their discoveries in the lab will translate to the patient bedside and eventually help those who suffer from dengue infection around the world.

The study is published in Science Translational Medicine.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 10 2015 | 8:55 AM IST

Next Story